Abstract
We performed hepatic arterial infusion chemotherapy (HAI) on 86 patients with unresectable hepatocellular carcinoma (HCC, 61 patients) or unresectable recurrent HCC after hepatectomy (25 patients). As drug therapy, 250 mg of 5-fluorouracil was injected daily for 14 days using a reservoir embedded in the subcutaneous layer. During this period, 0.4 mg/kg of doxorubicin and 0.12 mg/kg of mitomycin C suspended in Lipiodol Ultra-Fluide were also injected twice intra-arterially. This was defined as one course of HAI, and it was repeated every 3 months. In the patients with unresectable HCC, the 1-, 2-, and 3-year survival rates were 31.5%, 22.4%, and 10.7%, respectively, and the numbers of cases showing a complete response (CR), a partial response (PR), a minor response (MR), no change (NC), and progressive disease (PD) according to the Criteria for the Evaluation of the Clinical Effects of Solid Cancer Chemotherapy established by the Japan Society for Cancer Therapy were 1 (1.6%), 20 (32.8%), 5 (8.2%), 28 (45.9%), and 7 (11.5%), respectively. On the other hand, the 1-, 2-, and 3-year survival rates of the patients with unresectable recurrent HCC were 69.6%, 34.8%, and 14.9%, respectively. The rate of catheter patency after 1 year was 64.1%, and the mean catheter-patency period was 311.9 days. Patients in group A (CR+PR,n=21) survived significantly longer than those in group B (MR+NC+PD,n=40;P<0.05).
In conclusion, since responders to HAI achieve longer survival than nonresponders, the selection of effective drugs is important for this therapy.
Similar content being viewed by others
Abbreviations
- HCC:
-
hepatocellular carcinoma
- HAI:
-
hepatic arterial infusion chemotherapy
- CR:
-
complete response
- PR:
-
partial response
- MR:
-
minor response
- NC:
-
no change
- PD:
-
progressive disease
References
Arai Y, Kamimura N, Suyama K (1982) A method for subcutaneously retaining a catheter connected to a new silicone reservoir in intra-arterial infusion chemotherapy. Jpn J Cancer Chemother 9: 1838
Harada A, Nonami T, Kishimoto W, Nakao A, Takagi H (1992) Results of hepatic resection and postoperative arterial chemotherapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 31 [Suppl I]: S35
Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapys. J Jpn Soc Cancer Ther 28: 101
Liver Cancer Study Group of Japan (1989) The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 19: 98
Miura T, Idezuki Y, Wada T (1985) Intraarterial infusion chemotherapy for hepatic carcinomas using a totally implantable infusaid pump. Jpn J Cancer Chemother 12: 1949
Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, Kawano N, Morioka Y (1990) Postoperative recurrence of hepatocellular carcinoma. Ann Surg 211: 28
Nagasue N, Yukaya H, Hamada T, Hirose S, Kanashima R, Inokuchi K (1984) The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54: 1461
Nonami T, Takagi H (1989) The role of hepatic arterial infusion chemotherapy for hepatoma. Jpn J Gastroenterol 86: 1985
Nonami T, Isshiki K, Katoh H, Kishimoto W, Harada A, Nakao A, Takagi H (1991) The potential role of postoperatives hepatic artery chemotherapy in patients with high-risk hepatomas. Ann Surg 213: 222
Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M (1989) Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 64: 1586
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yasui, M., Nonami, T., Kurokawa, T. et al. Effects of hepatic arterial infusion chemotherapy on unresectable or recurrent hepatocellular carcinoma. Cancer Chemother. Pharmacol. 33 (Suppl 1), S139–S141 (1994). https://doi.org/10.1007/BF00686686
Issue Date:
DOI: https://doi.org/10.1007/BF00686686